SUMMARY Three newborn infants are reported who developed severe non-ketotic hypoglycaemia (blood glucose <1 I mmol/l; 19 * 8 mg/100 ml) within 6 hours of birth. All had inappropriately raised plasma insulin concentrations for the level of glycaemia, and required high rates of glucose infusion (> 15 mg glucose/kg per minute) to prevent symptoms of hypoglycaemia. Medical treatment (hydrocortisone, diazoxide, chlorothiazide, phenytoin, propranolol, and depot glucagon) was ineffective in preventing hypoglycaemia and all 3 infants were subjected to partial and then total pancreatectomy. The pathological features of nesidioblastosis are reported from quantitative immunohistochemical studies on the pancreata. These results together with those from metabolic and endocrine studies performed on the 3 infants during the investigation of the cause of the hypoglycaemia and during the perioperative and postoperative period are presented in detail in order to define a practical approach to the management of this difficult clinical problem in the neonate.
raised plasma insulin concentrations for the level of glycaemia, and required high rates of glucose infusion (> 15 mg glucose/kg per minute) to prevent symptoms of hypoglycaemia. Medical treatment (hydrocortisone, diazoxide, chlorothiazide, phenytoin, propranolol, and depot glucagon) was ineffective in preventing hypoglycaemia and all 3 infants were subjected to partial and then total pancreatectomy. The pathological features of nesidioblastosis are reported from quantitative immunohistochemical studies on the pancreata. These results together with those from metabolic and endocrine studies performed on the 3 infants during the investigation of the cause of the hypoglycaemia and during the perioperative and postoperative period are presented in detail in order to define a practical approach to the management of this difficult clinical problem in the neonate. Hyperinsulinism is a rare cause of severe persistent hypoglycaemia during the neonatal period. Nevertheless it is a diagnosis of importance since the hypoglycaemia may be exceedingly difficult to control, and associated with it is a high incidence of brain damage and subsequent mental retardation. ' In order to define a practical approach to the diagnosis and treatment of persistent neonatal hyperinsulinism we report studies on 3 infants with severe hypoglycaemia due to pancreatic nesidioblastosis who required total pancreatectomy to control the hypoglycaemia.
Clinical presentation of the infants
The relevant presenting clinical data are shown in Table 1 . The pregnancy in each case had been normal, and none of the mothers had had glycosuria or rhesus incompatibility. The infants developed symptoms due to hypoglycaemia within the first 6 hours of birth. Case 1 was 'jittery' from birth, Case 2 was hypotonic and had difficulty in feeding, Case 3 presented as an averted death at age 6 hours.2 Each infant resembled an infant of a diabetic mother (Fig. 1) .
Methods
Biochemical and endocrine assay methods. Blood samples were drawn initially from the infants through indwelling umbilical catheters. Immediately on withdrawing, blood (0 5-1 0 ml) was added to 5 ml ice-cold 10% perchloric acid for assay of intermediary metabolites. Blood (0 5 ml) was also added to a heparinised tube for assay of plasma insulin and cortisol; 0 9 ml was added to 0 1 ml aprotonin (Trasylol) containing 50 mmol/l EDTA for assay of plasma glucagon. Plasma was stored at -200C until assayed. Levels Rates of insulin release and biosynthesis, and islet content of adenosine triphosphate (ATP) were measured as follows.
Insulin release and ATP content Batches of 3 islets were incubated in 0 3 ml Krebs bicarbonate medium containing albumin (2 mg/ml) and glucose (0 4 or 20 mmol/l) for 2 hours at 370C.
After incubation 0 2 ml medium was separated from islets by sedimentation and the insulin concentration determined by radioimmunoassay using a charcoal method.'9 0 05 ml ice-cold 10% perchloric acid was added to the remaining 0 1 ml of medium containing the islets. The islets were disrupted by sonication and ATP concentration in aliquots of the sonicate was measured using a luciferase assay as described previously.20
Insulin and total protein biosynthesis Batches of islets were incubated at 370C for 90 minutes in 0 I ml Krebs bicarbonate medium containing 4 ,tCi (4,5-3H) leucine (53 LCi5, umol) , and glucose (0-4 or 20 mmol/l). The incorporation 498 Aynsley-Green, Polak, Bloom, Gough, Keeling, Ashcroft, Turner, and Baum of (3H) leucine into insulin plus proinsulin was measured using insulin-binding affinity columns, and into total islet protein using trichloracetic acid precipitation as described previously in detail.
Results
Initial investigations. Each infant had 2 blood samples drawn (one had 3) at about the time of presentation when hypoglycaemic. The results of the assays for plasma insulin and blood metabolites (Table 2 ) are compared with data from control infants of the same age. 22 The mean blood glucose value was 0-91 mmol/l (16c4 mg/l00ml) compared with 3*67 mmol/l (66 mg/100 ml) in the controls (P<0-01); mean plasma insulin level was considerably increased (28'7 v 6-8 ,uU/ml, P<0'01). Associated with the inappropriately raised plasma insulin values were significantly lower concentrations of blood 3- hydroxybutyrate (0'030 v 0 122 mmol/l, P<0'01) and thus total blood ketone bodies (P-hydroxybutyrate and acetoacetate). The mean concentrations of blood lactate and alanine were not appreciably different. The mean plasma glucagon concentration in Case 1 on day 1 when he was hypoglycaemic was 15 5 pmol/l (n = 3, range 15-24'0), considerably lower than the mean value of 65' 2 ± l *7 pmol/l in the controls. Mean initial plasma cortisol concentration in the 3 infants was 800 nmol/l (29 ,ug/ 100 ml), indicating a substantial response to hypoglycaemia.
The infants were given an intravenous glucose tolerance test (0'5 g glucose/kg) and a glucagon provocation test (0 1 mg/kg intramuscularly). One infant received glucagon twice. The mean basal and peak blood glucose and plasma insulin values for the two tests are shown in Table 3 . There was an inappropriate increase in plasma insulin for the low blood glucose concentrations in the basal samples Oral leucine (150 mg/kg) and intravenous arginine (0'5 g/kg over 30 minutes) were given to Case 1, with glucose infusion maintained throughout both tests at a constant rate of 15 mg/kg per minute. Despite this, the blood glucose concentration fell from 2'9 mmol/l (52 mg/100 ml) to 19 mmol/l (34 mg/100 ml) 60 minutes after giving leucine, with an increase of plasma insulin from 25 to 31 ,iU/ml. Arginine caused an increase in plasma insulin from 20 to 55 ,uU/ml within 20 minutes of the end of the infusion, with a fall in blood glucose from 2'5 to I * I mmol/1 (45 to 19-8 mg/l00 ml).
Response to initial medical treatment. Immediate correction of the presenting hypoglycaemia was attempted by giving a bolus of glucose (0'5 g/kg intravenously) followed by a continuous glucose infusion. In all 3 infants hypoglycaemia with convulsions recurred during the first 24 hours despite glucose infusions (mean rate 6 mg/kg per minute) and before the magnitude of the glucose requirement was appreciated fully. The rate of glucose infusion was increased rapidly to 15, 17 , and 25 mg/kg per minute respectively (Table 4 ) but despite these high infusion rates it was not possible to restore normoglycaemia although the infants no longer had symptoms.
Nesidioblastosis of the pancreas 499 Blood glucose concentrations increased in all 3 infants during the operation before resection of the pancreas (mean value 60 minutes after induction of anaesthesia being 10 0 mmol/l; 180 mg/100 ml). Portal vein blood samples drawn immediately before resection of the pancreas had a mean plasma insulin concentration of 87 ,uU/ml which fell in 2 infants to a mean value of 18 ,uU/ml after subtotal resection. Blood glucose values on return from the theatre were 16-6, 15-6, and 7 5 mmol/l (299, 281, and 135 mg/100 ml) respectively. None of the infants remained hyperglycaemic after the first 24 hours after surgery, and all again required glucose infusions to prevent hypoglycaemia.
Case 1
The subsequent course of Case 1 requires further comment, since experience with his management determined our treatment of the two others. During the first postoperative days, blood glucose concentrations were maintained initially on a glucose infusion and then on feeds at 2-to 3-hourly intervals.
Recurrent hypoglycaemia (mean blood glucose 2-0 mmol/l (36 mg/100 ml), mean plasma insulin 6 ,uU/ml) led to the reintroduction of diazoxide (20 mg/kg per day) and chlorothiazide (125 mg daily) without appreciable improvement. Addition of zinc protamine glucagon (0 5 mg intramuscularly 12 hourly) had an initial beneficial effect, but after 4 weeks of treatment recurrent hypoglycaemia again developed. Introduction of phenytoin23 24 and propranolol25 did not improve blood glucose concentrations. A 95% pancreatectomy was performed at age 3 months (see below). The pancreatic remnant from the previous operation appeared to have regenerated to the size of the original pancreas. Postoperatively, blood glucose concentrations remained initially between 3 5 and 6 0 mmolAl (63 and 108 mg/100 ml), but fell progressively to 1*9 mmol/l (34 mg/100 ml), associated with a convulsion. Reintroduction of diazoxide and chlorothiazide did not improve the situation. An attempt was made to increase blood ketone body concentrations as alternative fuels to glucose by giving a diet rich in medium chain triglycerides26 and then by giving growth hormone ( pancreatic polypeptide lying in acinar tissue and duct epithelieum (Fig. 4) . The results of quantitative analysis of pancreata from the controls and the patients are shown in In vitro studies on isolated islets of Langerhans.
Sections of pancreata from all 3 patients were prepared by collagenase digestion but only the yield of islets from Case 1 was sufficient to perform incubation studies.
Insulin release
In the absence of glucose, the rate of insulin release was 17 7 ± 3 2 ±U/islet per hour (n = 4). The rate of release was increased in the presence of 4 mmol/l glucose (39 5 ± 6 8 ,uU/islet per hour, n = 3) but no further increase was seen in the presence of 20 mmol/l glucose (44 9 ± 9-8 RU/islet per hour, n = 4). Polak and Bloom12 stressed the importance of the increased insulin: somatostatin cell ratio as a diagnostic feature of nesidioblastosis. In their series of 8 cases, there was a change in the ratio from about 2 insulin: 1 somatostatin cell seen in the fetus and normal neonate to 5 insulin: 1 somatostatin cell. The normal close anatomical relationship of these two cell types was also lost. Their observation, also present in our 3 patients, that the somatostatin content of the pancreata was less than half that seen in controls substantiates the implication from morphometry that somatostatin 'deficiency' is a major feature of this disease.
There is no information on the metabolic and secretory activities of normal neonatal human pancreatic islets despite detailed knowledge of islet function in experimental animals. For this reason it is difficult to state whether the isolated islets used in the present study in vitro showed normal or abnormal behaviour. However one feature of the result is of note: insulin release from the isolated islets was stimulated maximally by 4 mmol/l glucose and no further increase in secretion rate was elicited by 20 mmol/l glucose. Moreover the rate of insulin biosynthesis was also little affected by the presence of added glucose, even though the viability of these islets was attested to by the ATP content which was similar to that of collagenase-isolated rodent islets.20 35 These findings are in contrast to those in rat islets in which insulin biosynthesis and release respond markedly to changes in glucose concentration over the range 4-20 mmol/1.36 37 They also contrast with data obtained from islets from a 4-year-old girl with 'idiopathic' hypoglycaemia64 and from normal adult human islets maintained in tissue culture for one week ;38 in both these studies insulin release was stimulated by raising the glucose concentration from 3 * 3 to 16 7 mmol/l.
Thus the islets studied here show an abnormal sensitivity to glucose, with both biosynthesis and release being stimulated maximally by fairly low glucose concentrations, and this may contribute substantially to the hyperinsulinaemia. It is not known whether our infants had intrauterine hyperinsulinism. In favour of this are the facts that hyperinsulinism was demonstrated within hours of birth and that all three had a similar physical appearance, resembling that of an infant of a diabetic mother. None of the infants had hepatomegaly at birth, but all developed progressive liver enlargement during the first days. Diagnosis of hyperinsulinism. Table 8 lists the important diagnostic points for hyperinsulinism. The most important is the demonstration ofinappropriate plasma insulin values for the levels of glycaemia. Insulin release normally falls to very low levels when blood glucose concentrations decrease46 and the demonstration even of normal fasting levels of plasma insulin during severe hypoglycaemia implies a defect in the control of basal insulin release. The calculation of glucose infusion rate (in terms of mg/kg per minute) required to maintain normoglycaemia is more useful than calculation of glucose disappearance rate from an intravenous glucose tolerance test in that it gives a direct indication of glucose need and allows changes in condition or response to treatment to be recognisable immediately. It also obviates the need to perform a glucose tolerance test which carries the danger of severe hypoglycaemia soon after the injection of glucose (since the maintainance infusion of glucose needs to be stopped for the test). Thus the glucose tolerance test is unnecessary if glucose infusion rates greater than 10 mg/kg per minute are required to maintain Table 8 Diagnostic points for hyperinsulinism (1) Inappropriately raised plasma insulin concentrations for blood glucose values (2) Glucose infusion rate > 15 mg/kg per minute to maintain blood glucose level > 2 mmol/l (36 mg/ 100 ml)
Low blood ketone bodies during hypoglycaemia (4) Glycaemic response to glucagon despite hypoglycaemia normoglycaemia (the normal glucose production rate in the newborn infant is about 6 mg/kg per minute).47
The presence of low blood ketone body values support the diagnosis of hyperinsulinism since hypoglycaemia should normally induce the release of the counter-regulatory hormones glucagon, somatostatin, growth hormone, cortisol, and catecholamines, the end result being mobilisation of fat and generation of ketone bodies. Insulin prevents lipolysis so that the demonstration of non-ketotic hypoglycaemia strongly supports the diagnosis of hyperinsulinism. 48 Our results show that this is true also for the newborn infant.
An increase in blood glucose after glucagon during hypoglycaemia also favours hyperinsulinism, since most other hypoglycaemic conditions in infancy induce a starvation-like state with exhaustion of liver glycogen and a failure to increase blood glucose after glucagon. In nesidioblastosis however, the excess insulin secretion directs glucose into inappropriate glycogen formation, explaining the development of hepatomegaly in all cases and the results of the liver biopsy in Case 1.
Hirsch et al.49 reported the striking and prolonged effect of infusions of somatostatin in an infant with nesidioblastosis (see below). Somatostatin was not available for trial in our infants, but it may prove to be a useful diagnostic test.
Neither the leucine provocation test nor the response to arginine infusion in Case 1 helped in the diagnosis and each was potentially dangerous by causing hypoglycaemia despite a concurrent glucose infusion.
Initial treatment. The immediate priority is to increase blood glucose concentrations to prevent convulsions and brain damage. Glucose infusions alone even at high rates were insufficient to restore normoglycaemia in our infants and the addition of hydrocortisone did not improve blood glucose levels. Regular, or short-acting, glucagon had only a transient effect but was useful in an emergency to cover, for example, the time that glucose infusions were being resited. Zinc protamine glucagon was used with only transient success.
Of the 4 hormones present in the normal Islet of Langerhans, only somatostatin has an inhibitory effect on insulin release.50 The hormone inhibited insulin secretion in non-malignant insulinomas in release.51 Thus concurrent administration of somatostatin should abolish the insulin-stimulating effect of the glucose needed to correct hypoglycaemia. However, this treatment can only be temporary since somatostatin inhibits several other endocrine systems and the long-term effects of prolonged treatment are unknown.
The hyperglycaemic effect of adrenaline is due, in part, to a direct inhibitory effect on the B-cell.52 53 Cornblath and Schwartz3O recommended long-acting adrenaline (Susphrine) in the initial diagnostictherapeutic evaluation of severe neonatal hypoglycaemia, but this preparation is not available in the UK. Administration of propranolol, as used in adults with insulinomas,25 was without effect.
Diazoxide causes hyperglycaemia through inhibiting insulin release, through stimulating catecholamine secretion and mobilising glycogen. 54 There are few reports of the efficacy of diazoxide in neonatal nesidioblastosis.1 In general, there has been only a poor response, with at best a transient improvement even with doses of 20 mg/kg per day or more. Baker and Stanley29 stressed that only 2 of 9 infants with onset of hyperinsulinaemic hypoglycaemia during the first month of life responded to diazoxide, whereas it was effective in 14 of 16 infants presenting after the first month and during the first year. In some cases of infantile hyperinsulinism, diazoxide exacerbates hypoglycaemia.55-58 Nevertheless, from our experience some infants with nesidioblastosis may respond well initially; it is not clear why this improvement was not maintained.
The hyperglycaemic effect of diazoxide is enhanced in vitro, and in experimental animals in vivo, by concurrent adminstration of thiazide diuretics. 59 No beneficial effect was seen in these infants after the addition of chlorothiazide. Chlorpromazine also enhances diazoxide-induced hyperglycaemia60 but this combination of drugs was not tried. Phenytoin has a direct inhibitory effect on insulin secretion, and has been used in adults with insulinomas.23 24 No beneficial effect was observed when this drug was used in Case 1.
Streptozotocin is a drug which selectively destroys insulin-secreting cells, and has been used for the experimental induction of diabetes mellitus in animals, and for amelioration of hyperinsulinism in adults with malignant insulinomas.61 However, it is highly toxic, and this precludes its use in newborn infants.
An The complete clearance of pancreatic tissue from the common bile duct during total pancreatectomy is likely to impair its blood supply and may cause subsequent ischaemic stricture. Similarly, the destruction of the pancreaticoduodenal arteries which supply the duodenal loop may predispose to perforation, and an omental wrap to provide a source for revasculatisation and to seal perforations is an important safeguard. The preservation of the spleen is of major importance in view of the increased risk of infection after splenectomy. It should be straightforward to dissect the pancreas from the splenic artery but if this vessel has to be ligated the short gastric arteries will maintain splenic viability if the gastroepiploic arterial arcade is intact.
The need for surgery is difficult to define in the infant who appears to respond well to diazoxide. Case 2 illustrates the difficultics in managing an infant who appeared to be well controlled with blood glucose values consistently above 2 mmol/l with normal frequency of feeding, but who had episodes of severe hypoglycaemia for no apparent reason. This infant suffered hypoglycaemic convulsions during these periods despite close supervision in hospital. It was felt eventually that perseverance would impose an intolerable strain on the parents and expose the child to serious risk of brain damage. Subtotal pancreatectomy however, did not improve blood glucose homeostasis, and in fact the infant became glucose drip-dependent again until a total pancreatectomy was performed.
Management of diabetes after total pancreatectomy.
Immediate postoperative management Pancreatectomy for nesidioblastosis represents an acute change from hyperinsulinism to diabetes. The operation must be covered by a secure intravenous line to supply glucose, and, postoperatively, to supply water, sodium, potassium, and glucose to match an intravenous infusion of insulin. All 3 infants required insulin within 3 hours of the final stage of the operation, when blood glucose levels were already raised and the danger of a glucoseinduced diuresis presented itself. During the first 48 hours after operation, an insulin infusion (Actrapid*) was run at about 0 1 units/kg per hour. Monocomponent insulin was used from the outset to reduce insulin antibody formation.
Enteral feeding was soon begun with milk formula, starting with hourly feeds and gradually progressing to 2-hourly and 3-hourly feeds throughout the 24 hours. Pancrex powder was mixed with each feed *Novo.
starting at a dose of 50 mg of powder to each 100 ml of formula.
Once enteral feeding was established safely the transition was made to intermittent subcutaneous injections of Actrapid insulin, the dose being about 0 25 units/kg, 6 hourly. This dose was modified in response to measurements of blood glucose. When a reasonably stable state was achieved, generally 3 to 4 days after the initiation of enteral feeding, a transition was made to the long-term management regimen.
Long-term management Insulin. Case 1 was started on twice-daily subcutaneous Actrapid insulin. At age 10 months this was changed to once daily Monotard* insulin which was continued until age 2 years when a small dose of Actrapid insulin was combined as a single morning injection. This remains the current insulin regimen for this child.
Cases 2 and 3 were started on Monocomponent Ultralente* insulin since feeds taken at regular intervals throughout the 24 hours for several months theoretically would match the very long-acting Ultralente insulin more appropriately than intermittent doses of short-acting insulin. In Case 2 Ultralente was given as a single injection before the first feed of the day at about 0600 hours. After several months the blood glucose levels were noted to be high in the first few hours after the injection, with rather lower levels 16-24 hours later. Because of this, Ultralente was begun at 2200 hours before the last feed of the day in Case 3. In this way the time of greatest danger of hypoglycaemia was diverted to the afternoon and evening hours when it might be detected and dealt with more easily. In both Cases 2 and 3 the use of Ultralente was remarkably effective and trouble free. At age 1 year both of these children were changed to Leo Retardt insulin given before the first feed of the day at 0700 hours. The reason for this change was the wish to abandon the middle of the night feeds and to move to a shorter acting insulin. The overall dose of insulin the 3 children have required has been about 1 unit/kg body weight per 24 hours.
Feeds. Nornmal volumes of infant milk formula were given to the infants initially with the introduction of non-milk foods after age 3 months. Six feeds within the 24 hours were continued up to age 10-12 months.
The dose of Pancrex was initially 50 mg with each 100 ml of milk, but by age 1 year it had increased to 300 mg with the milk and 600 mg with the meals. The dose was adjusted according to the growth of the *Novo, tNordisk.
Nesidioblastosis of the pancreas 507 children and the macroscopical appearance of their stools. Currently all 3 children are feeding well and growing normally.
Neurological development. Hyperinsulinaemic hypoglycaemia during the first year of life is a potent cause of severe brain damage and mental retardation if it is not recognised and effectively treated.' Despite recurrent hypoglycaemia, sometimes associated with convulsions, these 3 infants, now aged 4, 21, and 2 years, appear to be developing normally. Regular assessment has shown that all 3 perform appropriately for their ages. Formal IQ tests have not been performed. Cases 1 and 3 have suffered febrile convulsions not associated with hypoglycaemia. The apparent satisfactory outcome of these infants may be due to the fact that although all three suffered recurrent hypoglycaemic convulsions, in no case were the symptoms allowed to persist for more than a few minutes, being terminated by glucose or glucagon.
